Molecular Medicine

, Volume 16, Issue 9–10, pp 389–399 | Cite as

APOE/C1/C4/C2 Gene Cluster Genotypes, Haplotypes and Lipid Levels in Prospective Coronary Heart Disease Risk Among UK Healthy Men

  • Gie Ken-Dror
  • Philippa J. Talmud
  • Steve E. Humphries
  • Fotios Drenos
Research Article


The role of common APOE variants on plasma lipids, particularly low density lipoprotein (LDL) levels, and coronary heart disease (CHD) risk is well known; the influence of variation in the other nearby apolipoprotein genes APOC1, APOC4 and APOC2 is unclear. This study examines the association between APOE/C1/C4/C2gene cluster variation using tagging SNPs and plasma lipid concentration along with risk of CHD in a prospective cohort. Genotypes for 11 common APOE/C1/C4/C2SNPs were determined in 2,767 middle-aged (49 to 64 years) men from the Second Northwick Park Heart Study, with 275 CHD events over a 15-year follow-up period. Seven SNPs showed significant associations with one or more lipid trait in univariate analysis. Multivariate and haplotype analysis showed that the APOE genotypes are most strongly associated with effects on LDL-C and apoB concentration (explaining 3.4% of the LDL-C variance) while the other SNPs in this gene cluster explained an additional 1.2%. Haplotypes in APOC2 and APOC4 were associated with modest effects on HDL-C and apoAI (explaining respectively 1.4% and 1.2%). Carriers of the APOE ε2 SNP had a significantly lower risk of CHD hazard ratio (HR) of 0.63 (95% confidence interval (CI): 0.42–0.95), as did carriers of the APOC2 SNP rs5127 (HR = 0.72, 95% CI: 0.56–0.93), while carriers of APOC1 SNP rs4803770 had higher risk of CHD (HR = 1.36, 95% CI: 1.04–1.78) compared with noncarriers. While the common APOE polymorphism explains the majority of the locus genetic determinants of plasma lipid levels, additional SNPs in the APOC1/C2 region may contribute to CHD risk, but these effects require confirmation.



We acknowledge the contribution of the late Professor George Miller (1939-2006) who was the PI on the NPHSII study. We thank Sarah Leigh for providing bioinformatics support. The British Heart Foundation support FD and SEH (RG2008/008). The NPHSII study was supported by the Medical Research Council, the US National Institutes of Health (NHLBI 33014) and DuPont Pharma. We also thank all the medical staff and patients who contributed to the NPHSII study and the Office for National Statistics (NHS) Central Registry for provision of mortality data.

Supplementary material

10020_2010_1609389_MOESM1_ESM.pdf (588 kb)
Supplementary material, approximately 586 KB.


  1. 1.
    Austin MA, Hokanson JE, Edwards KL. (1998) Hypertriglyceridemia as a cardiovascular risk factor. Am. J. Cardiol. 81:7B–12B.CrossRefGoogle Scholar
  2. 2.
    Castelli WP, Anderson K, Wilson PW, Levy D. (1992) Lipids and risk of coronary heart disease. The Framingham Study. Ann. Epidemiol. 2:23–28.CrossRefGoogle Scholar
  3. 3.
    Brunzell JD, Sniderman AD, Albers JJ, Kwiterovich PO Jr. (1984) Apoproteins B and A-I and coronary artery disease in humans. Arteriosclerosis. 4:79–83.CrossRefGoogle Scholar
  4. 4.
    Lusis AJ. (2000) Atherosclerosis. Nature. 407:233–41.CrossRefGoogle Scholar
  5. 5.
    Sing CF, Stengard JH, Kardia SL. (2003) Genes, environment, and cardiovascular disease. Arte-rioscler. Thromb. Vasc. Biol. 23:1190–6.CrossRefGoogle Scholar
  6. 6.
    Lusis AJ, Mar R, Pajukanta P. (2004) Genetics of atherosclerosis. Annu. Rev. Genomics Hum. Genet. 5:189–218.CrossRefGoogle Scholar
  7. 7.
    Beekman M, et al. (2002) Heritabilities of apolipo-protein and lipid levels in three countries. Twin Res. 5:87–97.CrossRefGoogle Scholar
  8. 8.
    Ehnholm C, Lukka M, Kuusi T, Nikkila E, Utermann G. (1986) Apolipoprotein E polymorphism in the Finnish population: gene frequencies and relation to lipoprotein concentrations. J. Lipid Res. 27:227–35.PubMedGoogle Scholar
  9. 9.
    Dallongeville J, Lussier-Cacan S, Davignon J. (1992) Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. J. Lipid Res. 33:447–54.PubMedGoogle Scholar
  10. 10.
    Strittmatter WJ, Bova Hill C. (2002) Molecular biology of apolipoprotein E. Curr. Opin. Lipidol. 13:119–123.CrossRefGoogle Scholar
  11. 11.
    Eichner JE, et al. (2002) Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am. J. Epidemiol. 155:487–95.CrossRefGoogle Scholar
  12. 12.
    Boerwinkle E, et al. (1987) The use of measured genotype information in the analysis of quantitative phenotypes in man. II. The role of the apolipoprotein E polymorphism in determining levels, variability, and covariability of cholesterol, betalipoprotein, and triglycerides in a sample of unrelated individuals. Am. J. Med. Genet. 27:567–82.CrossRefGoogle Scholar
  13. 13.
    Siest G, et al. (1995) Apolipoprotein E: an important gene and protein to follow in laboratory medicine. Clin. Chem. 41:1068–86.PubMedGoogle Scholar
  14. 14.
    Bennet AM, et al. (2007) Association of apolipopro-tein E genotypes with lipid levels and coronary risk. JAMA. 298:1300–11.CrossRefGoogle Scholar
  15. 15.
    Jong MC, Hofker MH, Havekes LM. (1999) Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler. Thromb. Vasc. Biol. 19:472–84.CrossRefGoogle Scholar
  16. 16.
    Weisgraber KH, et al. (1990) Apolipoprotein C-I modulates the interaction of apolipoprotein E with beta-migrating very low density lipopro-teins (beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptor-related protein. J. Biol. Chem. 265:22453–9.PubMedGoogle Scholar
  17. 17.
    Sehayek E, Eisenberg S. (1991) Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyc-eride-rich lipoproteins through the low density lipoprotein receptor pathway. J. Biol. Chem. 266:18259–67.PubMedGoogle Scholar
  18. 18.
    Pentikainen MO, Oksjoki R, Oorni K, Kovanen PT. (2002) Lipoprotein lipase in the arterial wall: linking LDL to the arterial extracellular matrix and much more. Arterioscler. Thromb. Vasc. Biol. 22:211–7.CrossRefGoogle Scholar
  19. 19.
    Breckenridge WC, Little JA, Steiner G, Chow A, Poapst M. (1978) Hypertriglyceridemia associated with deficiency of apolipoprotein C-II. N. Engl. J. Med. 298:1265–73.CrossRefGoogle Scholar
  20. 20.
    Shen Y, Lookene A, Nilsson S, Olivecrona G. (2002) Functional analyses of human apolipopro-tein CII by site-directed mutagenesis: identification of residues important for activation of lipoprotein lipase. J. Biol. Chem. 277:4334–42.CrossRefGoogle Scholar
  21. 21.
    Allan CM, Taylor S, Taylor JM. (1997) Two hepatic enhancers, HCR.1 and HCR.2, coordinate the liver expression of the entire human apolipoprotein E/C-I/C-IV/C-II gene cluster. J. Biol. Chem. 272:29113–9.CrossRefGoogle Scholar
  22. 22.
    Kotite L, Zhang LH, Yu Z, Burlingame AL, Havel RJ. (2003) Human apoC-IV: isolation, characterization, and immunochemical quantification in plasma and plasma lipoproteins. J. Lipid Res. 44:1387–94.CrossRefGoogle Scholar
  23. 23.
    Kamboh MI, Aston CE, Hamman RF. (2000) DNA sequence variation in human apolipopro-tein C4 gene and its effect on plasma lipid profile. Atherosclerosis. 152:193–201.CrossRefGoogle Scholar
  24. 24.
    Cooper JA, et al. (2000) Comparison of novel he-mostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation 102:2816–2822.CrossRefGoogle Scholar
  25. 25.
    Miller GJ, et al. (1995) The effects of quality and timing of venepuncture on markers of blood coagulation in healthy middle-aged men. Thromb. Haemost. 73:82–6.CrossRefGoogle Scholar
  26. 26.
    Miller GJ, Bauer KA, Barzegar S, Cooper JA, Rosenberg RD. (1996) Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease. Thromb. Haemost. 75:767–71.CrossRefGoogle Scholar
  27. 27.
    World Health Organization Regional Office for Europe. (1976) Myocardial Infarction Community Register. Copenhagen: World Health Organization. Public Health in Europe 5.Google Scholar
  28. 28.
    Drenos F, et al. (2009) Integrated associations of genotypes with multiple blood biomarkers linked to coronary heart disease risk. Hum. Mol. Genet. 18:2305–16.CrossRefGoogle Scholar
  29. 29.
    de Bakker PI, et al. (2005) Efficiency and power in genetic association studies. Nat. Genet. 37:1217–23.CrossRefGoogle Scholar
  30. 30.
    Bolla MK, Haddad L, Humphries SE, Winder AF, Day IN. (1995) High-throughput method for determination of apolipoprotein E genotypes with use of restriction digestion analysis by microplate array diagonal gel electrophoresis. Clin. Chem. 41:1599–604.PubMedGoogle Scholar
  31. 31.
    Day IN, Humphries SE. (1994) Electrophoresis for genotyping: microtiter array diagonal gel electrophoresis on horizontal polyacrylamide gels, hydrolink, or agarose. Anal. Biochem. 222:389–95.CrossRefGoogle Scholar
  32. 32.
    Stephens M, Scheet P. (2005) Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am. J. Hum. Genet. 76:449–62.CrossRefGoogle Scholar
  33. 33.
    Stephens M, Smith NJ, Donnelly P. (2001) A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68:978–89.CrossRefGoogle Scholar
  34. 34.
    Graham RR, et al. (2001) Genetic linkage and transmission disequilibrium of marker haplo-types at chromosome 1q41 in human systemic lupus erythematosus. Arthritis Res 3:299–305.CrossRefGoogle Scholar
  35. 35.
    Marchini J, et al. (2006) A comparison of phasing algorithms for trios and unrelated individuals. Am. J. Hum. Genet. 78:437–50.CrossRefGoogle Scholar
  36. 36.
    Rothman KJ. (1990) No adjustments are needed for multiple comparisons. Epidemiology 1:43–6.CrossRefGoogle Scholar
  37. 37.
    Eichenbaum-Voline S, et al. (2004) Linkage and association between distinct variants of the APOA1/C3/A4/A5 gene cluster and familial combined hyperlipidemia. Arterioscler. Thromb. Vase. Biol. 24:167–74.CrossRefGoogle Scholar
  38. 38.
    Lai CQ, et al. (2004) Influence of the APOA5 locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham Heart Study. J. Lipid Res. 45:2096–105.CrossRefGoogle Scholar
  39. 39.
    Talmud PJ, et al. (2009) Genecentric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip. Am. J. Hum. Genet. 85:628–42.CrossRefGoogle Scholar
  40. 40.
    Isaacs A, et al. (2007) Heritabilities, apolipopro-tein E, and effects of inbreeding on plasma lipids in a genetically isolated population: the Erasmus Rucphen Family Study. Eur. J. Epidemiol. 22:99–105.CrossRefGoogle Scholar
  41. 41.
    Klos K, etal. (2008) APOE/C1/C4/C2 hepatic control region polymorphism influences plasma apoE and LDL cholesterol levels. Hum. Mol. Genet. 17:2039–46.CrossRefGoogle Scholar
  42. 42.
    North KE, et al. (2006) Linkage analysis of LDL cholesterol in American Indian populations: the Strong Heart Family Study. J. Lipid Res. 47:59–66.CrossRefGoogle Scholar
  43. 43.
    Willer CJ, et al. (2008) Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat. Genet. 40:161–9.CrossRefGoogle Scholar
  44. 44.
    Curtiss LK. (2000) ApoE in atherosclerosis: a protein with multiple hats. Arterioseler. Thromb. Vase. Biol. 20:1852–3.CrossRefGoogle Scholar
  45. 45.
    Artiga MJ, et al. (1998) Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene. FEBS Lett. 421:105–8.CrossRefGoogle Scholar
  46. 46.
    Lambert JC, et al. (1998) A new polymorphism in the APOE promoter associated with risk of developing Alzheimer′s disease. Hum. Mol. Genet. 7:533–40.CrossRefGoogle Scholar
  47. 47.
    Lambert JC, et al. (2000) Independent association of an APOE gene promoter polymorphism with increased risk of myocardial infarction and decreased APOE plasma concentrations-the ECTIM study. Hum. Mol. Genet. 9:57–61.CrossRefGoogle Scholar
  48. 48.
    Moreno JA, et al. (2003) The influence of the apolipoprotein E gene promoter (−219G/T) polymorphism on postprandial lipoprotein metabolism in young normolipemic males. J. Lipid Res. 44:2059–64.CrossRefGoogle Scholar
  49. 49.
    Moreno JA, et al. (2005) The apolipoprotein E gene promoter (−219G/T) polymorphism determines insulin sensitivity in response to dietary fat in healthy young adults. J. Nutr. 135:2535–40.CrossRefGoogle Scholar
  50. 50.
    Viitanen L, et al. (2001) Apolipoprotein E gene promoter (−219G/T) polymorphism is associated with premature coronary heart disease. J. Mol. Med. 79:732–7.CrossRefGoogle Scholar
  51. 51.
    Chen XH, et al. (2004) Evidence of admixture from haplotyping in an epidemiological study of UK Caucasian males: implications for association analyses. Hum. Hered. 57:142–55.CrossRefGoogle Scholar

Copyright information

© The Feinstein Institute for Medical Research 2010

Authors and Affiliations

  • Gie Ken-Dror
    • 1
  • Philippa J. Talmud
    • 1
  • Steve E. Humphries
    • 1
  • Fotios Drenos
    • 1
  1. 1.Centre for Cardiovascular Genetics, BHF Laboratories, The Rayne Building, Department of MedicineRoyal Free and University College Medical SchoolLondonUK

Personalised recommendations